PTGIR and pulmonary arterial hypertension: PAH-specific therapeutic approaches concentrate on these characteristics, with drugs targeting endothelin receptors (e.g., macitentan, bosentan), phosphodiesterase-5 (e.g., sildenafil), or the prostacyclin receptor (e.g., beraprost) [10,11].